The MAA first engaged with Amplo Biotechnologies at the 2019 Brisbane Conference. We are delighted to report that Patricio Sepulveda, CEO, is offering to share updated information on “what they are doing and where they are at”. Patricio reports that 35 different genes have now been identified to capture more people with Congenital Myasthenia Syndrome. This knowledge is important in providing the correct treatment. Patients, Clinicians and Carers are invited to attend the following information sessions. Australians can join at either 7am on August 14th (choose the US option) or 7pm on August 14th (choose the UK option). The session is expected to run for 45 minutes. Written questions will be answered on the day or by follow-up email.

Register utilising the QR code or link found in the flyer below. If you are sero-negative MG, please consider joining the webinar as some patients are being diagnosed quite late in life.

AMPLO IS DELIGHTED TO SHARE THE LATEST ADVANCEMENTS IN ITS GENE THERAPY FOR CONGENITAL MYASTHENIC SYNDROME. THIS IS A FREE WEBINAR FOR PATIENTS, CARERS AND CLINICIANS

Follow the link to register:

Tuesday 13th Aug, 5pm US EST
Wednesday 14th Aug, 10 am UK/GMT+1